hyperparathyroidism - ορισμός. Τι είναι το hyperparathyroidism
Diclib.com
Λεξικό ChatGPT
Εισάγετε μια λέξη ή φράση σε οποιαδήποτε γλώσσα 👆
Γλώσσα:

Μετάφραση και ανάλυση λέξεων από την τεχνητή νοημοσύνη ChatGPT

Σε αυτήν τη σελίδα μπορείτε να λάβετε μια λεπτομερή ανάλυση μιας λέξης ή μιας φράσης, η οποία δημιουργήθηκε χρησιμοποιώντας το ChatGPT, την καλύτερη τεχνολογία τεχνητής νοημοσύνης μέχρι σήμερα:

  • πώς χρησιμοποιείται η λέξη
  • συχνότητα χρήσης
  • χρησιμοποιείται πιο συχνά στον προφορικό ή γραπτό λόγο
  • επιλογές μετάφρασης λέξεων
  • παραδείγματα χρήσης (πολλές φράσεις με μετάφραση)
  • ετυμολογία

Τι (ποιος) είναι hyperparathyroidism - ορισμός

WEIGHT GAIN
Sestamibi scan for diagnosing hyperparathyroidism; Hyperparathyroidism,; HyperPTH; Hyper-PTH
  • [[Parathyroid adenoma]].
  • Calcification in the brain due to hyperparathyroidism
  • Pepper & Salt, classical X-Ray appearance of hyperparathyroidisim

hyperparathyroidism         
[?h??p??par?'???r??d?z(?)m]
¦ noun Medicine an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium.
Derivatives
hyperparathyroid adjective
Hyperparathyroidism         
Hyperparathyroidism is an increase in parathyroid hormone (PTH) levels in the blood. This occurs from a disorder either within the parathyroid glands (primary hyperparathyroidism) or as response to external stimuli (secondary hyperparathyroidism).
Primary hyperparathyroidism         
HUMAN DISEASE
Primary Hyperparathyroidism; Hyperparathyroidism, primary; PHPTH; PHPT; Normocalcemic Primary Hyperparathyroidism
Primary hyperparathyroidism (or PHPT) is a medical condition where the parathyroid gland (or a benign tumor within it) produce excess amounts of parathyroid hormone (PTH). The symptoms of the condition relate to the resulting elevated serum calcium (hypercalcemia), which can cause digestive symptoms, kidney stones, psychiatric abnormalities, and bone disease.

Βικιπαίδεια

Hyperparathyroidism

Hyperparathyroidism is an increase in parathyroid hormone (PTH) levels in the blood. This occurs from a disorder either within the parathyroid glands (primary hyperparathyroidism) or as response to external stimuli (secondary hyperparathyroidism). Symptoms of hyperparathyroidism are caused by inappropriately normal or elevated blood calcium leaving the bones and flowing into the blood stream in response to increased production of parathyroid hormone. In healthy people, when blood calcium levels are high, parathyroid hormone levels should be low. With long-standing hyperparathyroidism, the most common symptom is kidney stones. Other symptoms may include bone pain, weakness, depression, confusion, and increased urination. Both primary and secondary may result in osteoporosis (weakening of the bones).

In 80% of cases, primary hyperparathyroidism is due to a single benign tumor known as a parathyroid adenoma. Most of the remainder are due to several of these adenomas. Very rarely it may be due to parathyroid cancer. Secondary hyperparathyroidism typically occurs due to vitamin D deficiency, chronic kidney disease, or other causes of low blood calcium. The diagnosis of primary hyperparathyroidism is made by finding elevated calcium and PTH in the blood.

Primary hyperparathyroidism may only be cured by removing the adenoma or overactive parathyroid glands. In those without symptoms, mildly increased blood calcium levels, normal kidneys, and normal bone density monitoring may be all that is required. The medication cinacalcet may also be used to decrease PTH levels in those unable to have surgery although it is not a cure. In those with very high blood calcium levels, treatment may include large amounts of intravenous normal saline. Low vitamin D should be corrected in those with secondary hyperparathyroidism but low Vitamin D pre-surgery is controversial for those with primary hyperparathyroidism. Low vitamin D levels should be corrected post-parathyroidectomy.

Primary hyperparathyroidism is the most common type. In the developed world, between one and four per thousand people are affected. It occurs three times more often in women than men and is often diagnosed between the ages of 50 and 60 but is not uncommon before then. The disease was first described in the 1700s. In the late 1800s, it was determined to be related to the parathyroid. Surgery as a treatment was first carried out in 1925.

Παραδείγματα από το σώμα κειμένου για hyperparathyroidism
1. Your call. (Nathan Sheva) Teva Pharmaceuticals and Barr Laboratories, which Teva is buying, face a patent infringement challenge after filing requests to market generic versions of Sensipar tablets, which are used to treat secondary hyperparathyroidism in dialysis patients with chronic kidney disease.